0002103906-26-000001.txt : 20260122 0002103906-26-000001.hdr.sgml : 20260122 20260122163459 ACCESSION NUMBER: 0002103906-26-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20260122 DATE AS OF CHANGE: 20260122 EFFECTIVENESS DATE: 20260122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NBO Pharma Inc. CENTRAL INDEX KEY: 0002103906 ORGANIZATION NAME: EIN: 862318348 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-570878 FILM NUMBER: 26552185 BUSINESS ADDRESS: STREET 1: 64 QUARRY LANE CITY: BEDFORD STATE: NY ZIP: 10506 BUSINESS PHONE: 914-645-1130 MAIL ADDRESS: STREET 1: 64 QUARRY LANE CITY: BEDFORD STATE: NY ZIP: 10506 D 1 primary_doc.xml X0708 D LIVE 0002103906 NBO Pharma Inc. 64 QUARRY LANE BEDFORD NY NEW YORK 10506 914-645-1130 DELAWARE NBO Pharma LLC None Corporation true 2021 Fredric David Price 64 Quarry Lane Bedford NY NEW YORK 10506 Executive Officer Director Robert Friedman 1118 Belle Ave Teaneck NJ NEW JERSEY 07666 Director Colin Foster 117 Beecher Road Woodbridge CT CONNECTICUT 06525 Director Bard Geesaman 2303 Parkview Lane Marlboro MA MASSACHUSETTS 01752 Director Pharmaceuticals Decline to Disclose 06c false 2025-06-12 false true true false 10000 Paulson Investment Company, LLC 5670 None None 10220 SW Greenburg Road Suite 380 Portland OR OREGON 97223 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA IA IOWA KS KANSAS MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MS MISSISSIPPI MO MISSOURI MT MONTANA NV NEVADA NH NEW HAMPSHIRE NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA ND NORTH DAKOTA OH OHIO OK OKLAHOMA OR OREGON PA PENNSYLVANIA SC SOUTH CAROLINA SD SOUTH DAKOTA TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON false 7640217 7640217 0 The total amount sold includes (i) $625,000 from conversion of SAFES and (ii) $7,015,217 from cash investment. false 93 946978 0 Issuer provided placement agent (i) 13% of gross proceeds received from qualifying investors (ii) a $35,000 non-accountable expense fee and (iii) a number of warrants equal to 15% of the total number of shares sold to qualifying investors in the offering. 0 false NBO Pharma Inc. /s/ Fredric D. Price Fredric D. Price Chief Executive Officer 2026-01-22